# Detrol LA In Men With Overactive Bladder.

> **NCT00282932** · PHASE4 · COMPLETED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 600 (—)

## Conditions studied

- Overactive Bladder (OAB)

## Interventions

- **DRUG:** Detrol LA

## Key facts

- **NCT ID:** NCT00282932
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2007-05-01
- **Final completion:** 2007-05-14
- **Target enrollment:** 600 (—)
- **Last updated:** 2021-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00282932

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00282932, "Detrol LA In Men With Overactive Bladder.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00282932. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*